Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37890124.
- Also identified by DOI 10.1200/JCO.23.01196.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Trial-level surrogacy is critical before early response endpoints are used to approve new therapies.
Medical subject headings
- Neoadjuvant Therapy
- Rectal Neoplasms